Startups & growth Analysis
Immunartes takes two approaches to preventing hard-to-fight staph infections
Immunartes is developing a vaccine and an antibody for different prevention needs, with both programs still in preclinical research.
I
Immunartes develops preclinical vaccine and antibody candidates intended to prevent Staphylococcus aureus infections.
Overview
Immunartes develops preventive approaches to Staphylococcus aureus infection. Its preclinical programs include a vaccine intended to generate longer-term immunity and a monoclonal antibody intended for high-risk hospital settings.
The antibody program received a CARB-X award commitment, and the company has reported NIH contract support for its vaccine research.
- Legal name reported in 2022
- IMMUNARTES LLC
Loading profile details…
Industries
- Industry category
- Healthcare & Life Sciences
- Specific industry
- Biotech Research
Classification sources and history
Biotech Research · Business involvement
As of 2026-11-09
Loading recent changes…
Sources & editorial review
(3)
- Immunartes programs and team
- CARB-X Immunartes award announcement
- Immunartes NIH contract announcement
Editorial profile by MoneyMakers. Sources reviewed .
